Business
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
Total revenues of €127.0 million compared to €116.6 million in the first nine months of 2024Cash and cash equivalents of €143.5 million at end of September 2025Financial flexibility enhanced with successful debt refinancing in October 20251Lyme disease Phase 3 study VALOR on trackUpdated 2025 financial outlook confirmed1 Saint-Herblain (France), November 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the f
About this update from Valneva Se
[{"type":"image","alt":"VALNEVA","displaySize":"","headline":null,"caption":"VALNEVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9l2h5dKc1PlSY26lXUAWsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6","width":300,"height":44}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenues of €127.0 million compared to €116.6 million in the first nine months of 2024","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents of €143.5 million at end of September 2025","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Financial flexibility enhanced with successful debt refinancing in October 20251","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"Lyme disease Phase 3 study VALOR on track","length":41,"tagName":"p"}]},{"val":[{"type":"text","content":"Updated 2025 financial outlook confirmed1","length":41,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":322,"olType":false},{"type":"text","content":"Saint-Herblain (France), November 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of the year, ended September 30, 2025. The condensed consolidated interim financial results are available on the Company’s website (Financial Reports – Valneva).","length":355,"tagName":"p"},{"type":"text","content":"Valneva will provide a live webcast of its nine-month 2025 results conference call beginning at 3 p.m. CET / 9 a.m. ET today. This webcast will also be available on the Company’s website. Please refer to this link: https://edge.media-server.com/mmc/p/okg8hcar","length":260,"tagName":"p"},{"type":"text","content":"Nine-Month Financial Update","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenues were €127.0 million compared to €116.6 million in the first nine months of 2024, an increase of 8.9%","length":115,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":115,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Product sales reache...